nilvadipine has been researched along with Brain Vascular Disorders in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The drug is equally effective in treating hypertension in elderly and younger patients and does not appear to adversely affect glucose or lipid metabolism." | 6.39 | Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. ( Brogden, RN; McTavish, D, 1995) |
| "nilvadipine or terazosin was administered for 2 weeks in a randomized crossover manner." | 2.69 | Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke. ( Abe, I; Fujishima, M; Hasuo, Y; Nishino, Y; Onaka, U; Setoguchi, M, 1998) |
| "The drug is equally effective in treating hypertension in elderly and younger patients and does not appear to adversely affect glucose or lipid metabolism." | 2.39 | Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. ( Brogden, RN; McTavish, D, 1995) |
| "The development of Alzheimer's disease (AD) is generally thought to correlate with cerebral accumulation of Abeta." | 1.32 | Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. ( Crawford, F; Crescentini, R; Humphrey, J; Mullan, M; Paris, D; Patel, N; Quadros, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Paris, D | 1 |
| Quadros, A | 1 |
| Humphrey, J | 1 |
| Patel, N | 1 |
| Crescentini, R | 1 |
| Crawford, F | 1 |
| Mullan, M | 1 |
| Brogden, RN | 1 |
| McTavish, D | 1 |
| Takakura, S | 1 |
| Furuichi, Y | 1 |
| Yamamoto, T | 1 |
| Ogawa, T | 1 |
| Satoh, H | 1 |
| Mori, J | 1 |
| Setoguchi, M | 1 |
| Onaka, U | 1 |
| Abe, I | 1 |
| Hasuo, Y | 1 |
| Nishino, Y | 1 |
| Fujishima, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nilvadipine and Brain Vascular Disorders
| Article | Year |
|---|---|
Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
Topics: Aging; Angina Pectoris; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular | 1995 |
1 trial available for nilvadipine and Brain Vascular Disorders
| Article | Year |
|---|---|
Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aging; Blood Pressure Monitoring, Ambulatory; | 1998 |
2 other studies available for nilvadipine and Brain Vascular Disorders
| Article | Year |
|---|---|
Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Aorta; Calcium Channel B | 2004 |
Effect of nilvadipine on the development of neurological deficits in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Calcium Channel Blockers; Cerebrovascular Disorders; Eating; Hypertension; Male; Nifedipine | 1994 |